After treatment with sorafenib, hepatoma cells upregulate miRNA-375 expression and downregulate the expression of platelet-derived growth factor C (PDGFC), inhibit the phosphorylation of its downstream signaling pathways ERK1/2, AKT, and play a role in inhibiting angiogenesis (Wang, 2017). Here, PDGFC is linked to hepatocellular carcinoma.